<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03551808</url>
  </required_header>
  <id_info>
    <org_study_id>96316</org_study_id>
    <nct_id>NCT03551808</nct_id>
  </id_info>
  <brief_title>Prophylactic Effect of Ketorolac Tromethamine on the Cystoid Macular Edema After Phacoemulsification in Diabetic Patients</brief_title>
  <official_title>Prophylactic Effect of Ketorolac Tromethamine on the Cystoid Macular Edema After Phacoemulsification in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is determining the prophylactic effect of ketorolac tromethamine drop&#xD;
      0.5% eye drop on the functional and anatomical ocular characteristics of the diabetic&#xD;
      patients after the phacoemulsification surgery. Cystoid macular edema (CME) is a ocular&#xD;
      disease which the retinal thickness is increased by 30 % incidence at least or the visual&#xD;
      acuity is decreased to 20/40 according to clinical definition. Ketorolac tromethamine is an&#xD;
      non steroidal anti inflammatory medication which is used for treatment and Prophylactic for&#xD;
      CME. Teh aim of this study is prophylactic effect of ketorolac tromethamine on choroidal and&#xD;
      retinal thickness after Phacoemulsification in Diabetic Patients. In this randomized clinical&#xD;
      trial, 102 eyes of 102 diabetic patients were included. All patients were undergone&#xD;
      phacoemulsification surgery at Torfeh Eye Hospital between September 2015 and January 2017.&#xD;
      To evaluate the prophylactic effect of ketorolac tromethamine topical eye drop, all cases&#xD;
      were asked to apply it one day before the s:surgery in each 8 hours and continue it for 4&#xD;
      weeks after the surgery. Controls were not received placebo. All study population were&#xD;
      examined using Snellen visual acuity chart, enhanced depth imaging optical coherence&#xD;
      tomography (EDI-OCT). All patients were followed at 6, 12 and 24 weeks after the cataract&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected visual acuity</measure>
    <time_frame>24 weeks after the surgery</time_frame>
    <description>Snellen visual acuity chart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>retinal and choroidal thickness</measure>
    <time_frame>24 weeks after the surgery</time_frame>
    <description>enhanced depth imaging optical coherence tomography (EDI-OCT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Cystoid Macular Edema After Phacoemulsification</condition>
  <arm_group>
    <arm_group_label>installation of Ketorolac Tromethamine Eye Drop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>not receiving placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>using of Ketorolac Tromethamine Eye Drop</intervention_name>
    <description>using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery</description>
    <arm_group_label>installation of Ketorolac Tromethamine Eye Drop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients (type II) with cataract&#xD;
&#xD;
          -  Eligible patients at age range of 20 to 95 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cases with a diabetic macular edema&#xD;
&#xD;
          -  proliferative diabetic retinopathy&#xD;
&#xD;
          -  history of intravitreal injection of bevacizumab and macular photocoagulation prior&#xD;
             three months to the cataract surgery&#xD;
&#xD;
          -  glaucoma&#xD;
&#xD;
          -  refractive errors of more than Â±6 diopters&#xD;
&#xD;
          -  history of previous ocular surgery&#xD;
&#xD;
          -  ocular pathological disorders&#xD;
&#xD;
          -  history of systemic diseases&#xD;
&#xD;
          -  history of medications which have a side effect on the retinal thickness&#xD;
&#xD;
          -  patients with a follow up of less than 6 months&#xD;
&#xD;
          -  individuals with any intraoperative complications will be excluded from this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hossien Mohammad Rabie, MD</last_name>
    <phone>9822591616</phone>
    <email>labbafi@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hossien Mohammad Rabie, MD</last_name>
      <phone>9822591616</phone>
      <email>labbafi@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>May 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2018</study_first_posted>
  <last_update_submitted>May 29, 2018</last_update_submitted>
  <last_update_submitted_qc>May 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

